See more : Atul Auto Limited (ATULAUTO.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Adicet Bio, Inc. (ACET) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Adicet Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Synchrony Financial (SFE.DE) Income Statement Analysis – Financial Results
- OAT Agrio Co., Ltd. (4979.T) Income Statement Analysis – Financial Results
- Bingshan Refrigeration & Heat Transfer Technologies Co., Ltd. (200530.SZ) Income Statement Analysis – Financial Results
- eDreams ODIGEO S.A. (EDEMY) Income Statement Analysis – Financial Results
- Global Blood Therapeutics, Inc. (GBT) Income Statement Analysis – Financial Results
Adicet Bio, Inc. (ACET)
About Adicet Bio, Inc.
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 24.99M | 9.73M | 17.90M | 995.00K | 8.18M | 558.52M | 546.95M | 510.18M | 499.69M | 499.69M | 444.39M | 412.43M | 346.63M | 322.65M | 359.59M |
| Cost of Revenue | 6.10M | 5.01M | 0.00 | 0.00 | 125.00K | 80.00K | 5.00K | 411.52M | 395.48M | 401.42M | 401.42M | 362.36M | 346.59M | 292.48M | 267.03M | 292.29M |
| Gross Profit | -6.10M | 19.98M | 9.73M | 17.90M | 870.00K | 8.10M | 558.52M | 135.43M | 114.70M | 98.27M | 98.27M | 82.03M | 65.84M | 54.16M | 55.62M | 67.31M |
| Gross Profit Ratio | 0.00% | 79.96% | 100.00% | 100.00% | 87.44% | 99.02% | 100.00% | 24.76% | 22.48% | 19.67% | 19.67% | 18.46% | 15.96% | 15.62% | 17.24% | 18.72% |
| Research & Development | 106.04M | 71.25M | 48.94M | 34.33M | 23.69M | 14.72M | 16.84M | 5.94M | 5.22M | 2.83M | 0.00 | 0.00 | 0.00 | 0.00 | 153.00K | 506.00K |
| General & Administrative | 26.53M | 26.30M | 22.22M | 22.76M | 8.69M | 8.43M | 76.82M | 73.16M | 65.21M | 61.02M | 63.86M | 56.67M | 49.29M | 44.72M | 43.57M | 45.42M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -74.78M | -73.16M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 26.53M | 26.30M | 22.22M | 22.76M | 8.69M | 8.43M | 2.04M | 1.00K | 65.21M | 61.02M | 63.86M | 56.67M | 49.29M | 44.72M | 43.57M | 45.42M |
| Other Expenses | 19.46M | -919.00K | -606.00K | -953.00K | 2.33M | 4.53M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 152.04M | 97.54M | 71.16M | 57.09M | 32.38M | 23.15M | 18.88M | 1.00K | 70.43M | 63.86M | 63.86M | 56.67M | 49.29M | 44.72M | 43.73M | 45.93M |
| Cost & Expenses | 152.04M | 97.54M | 71.16M | 57.09M | 32.38M | 23.15M | 18.88M | 1.00K | 465.91M | 465.27M | 465.27M | 419.02M | 395.88M | 337.19M | 310.75M | 338.21M |
| Interest Income | 9.95M | 3.76M | 91.00K | 785.00K | 938.00K | 543.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 80.00K | 176.00K | 134.00K | 0.00 | 0.00 | 7.00M | 3.95M | 2.10M | 2.12M | 2.12M | 2.63M | 1.57M | 230.00K | 98.00K | 145.00K |
| Depreciation & Amortization | 6.10M | 5.01M | 4.07M | 1.95M | 1.24M | 80.00K | 5.00K | 11.85M | 8.09M | 6.94M | 6.94M | 6.94M | 5.50M | 2.80M | 1.87M | 2.38M |
| EBITDA | -136.54M | -64.70M | -60.41M | -37.41M | -26.88M | -13.74M | -33.77M | -1.00K | 54.87M | 43.62M | 43.62M | 34.31M | 24.03M | 13.23M | 14.70M | 24.71M |
| EBITDA Ratio | 0.00% | -278.95% | -636.67% | -219.85% | -2,701.61% | -105.93% | -3.38% | 0.00% | 10.75% | 8.73% | 8.73% | 7.72% | 5.83% | 3.82% | 4.55% | 6.87% |
| Operating Income | -152.04M | -72.55M | -61.43M | -39.19M | -31.39M | -14.96M | -18.88M | -1.00K | 44.27M | 34.42M | 34.42M | 25.37M | 16.55M | 9.44M | 11.89M | 21.38M |
| Operating Income Ratio | 0.00% | -290.32% | -631.38% | -218.91% | -3,154.57% | -182.91% | -3.38% | 0.00% | 8.68% | 6.89% | 6.89% | 5.71% | 4.01% | 2.72% | 3.69% | 5.94% |
| Total Other Income/Expenses | 9.38M | 2.76M | -691.00K | -302.00K | 3.27M | 5.08M | -14.90M | 0.00 | 402.00K | 134.00K | 134.00K | -626.00K | 412.00K | 765.00K | 839.00K | 812.00K |
| Income Before Tax | -142.66M | -69.79M | -62.12M | -39.49M | -28.12M | -9.89M | -33.78M | -1.00K | 44.67M | 34.55M | 34.55M | 24.74M | 16.96M | 10.20M | 12.73M | 22.19M |
| Income Before Tax Ratio | 0.00% | -279.27% | -638.48% | -220.59% | -2,826.03% | -120.87% | -6.05% | 0.00% | 8.76% | 6.91% | 6.91% | 5.57% | 4.11% | 2.94% | 3.95% | 6.17% |
| Income Tax Expense | 0.00 | -2.76M | -125.00K | -2.82M | 19.00K | -589.00K | 19.09M | 20.38M | 15.67M | 12.22M | 12.22M | 7.76M | 7.99M | 3.62M | 4.10M | 8.72M |
| Net Income | -142.66M | -67.03M | -62.00M | -36.68M | -28.14M | -9.30M | -33.78M | -1.00K | 29.00M | 22.33M | 22.33M | 16.98M | 8.97M | 6.58M | 8.63M | 13.47M |
| Net Income Ratio | 0.00% | -268.22% | -637.19% | -204.87% | -2,827.94% | -113.67% | -6.05% | 0.00% | 5.68% | 4.47% | 4.47% | 3.82% | 2.17% | 1.90% | 2.67% | 3.75% |
| EPS | -3.31 | -1.63 | -2.00 | -5.01 | -1.52 | -0.31 | -1.26 | 0.00 | 1.18 | 0.94 | 0.94 | 0.73 | 0.40 | 0.30 | 0.40 | 0.63 |
| EPS Diluted | -3.31 | -1.63 | -2.00 | -5.01 | -1.52 | -0.31 | -1.25 | 0.00 | 1.16 | 0.93 | 0.93 | 0.72 | 0.39 | 0.30 | 0.39 | 0.62 |
| Weighted Avg Shares Out | 43.04M | 41.08M | 30.95M | 7.32M | 18.56M | 29.80M | 26.77M | 28.05M | 24.50M | 23.67M | 23.67M | 23.26M | 22.67M | 21.86M | 21.43M | 21.30M |
| Weighted Avg Shares Out (Dil) | 43.04M | 41.08M | 30.95M | 7.32M | 18.56M | 29.80M | 26.97M | 28.05M | 24.99M | 24.02M | 24.02M | 23.46M | 22.84M | 22.07M | 21.86M | 21.70M |
Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will...
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on April 30, 2024....
Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that an abstract featuring new preclinical data highlighting ADI-270,...
Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer will...
Why Adicet Bio (ACET) Stock Might be a Great Pick
Adicet Bio (ACET) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?
Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on March 28, 2024....
The Penny Stock A-List: 7 High-Profile Companies on the Verge of Greatness
In most cases, investors should stay away from penny stocks. They're wild, they're unpredictable and they tend to lose their stakeholders money more so than they return.
Adicet Bio (ACET) Loses -16.39% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Adicet Bio (ACET) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock...
ACET Stock Earnings: Adicet Bio Meets EPS for Q4 2023
Adicet Bio (NASDAQ: ACET ) just reported results for the fourth quarter of 2023. Adicet Bio reported earnings per share of -69 cents.
Source: https://incomestatements.info
Category: Stock Reports